Agios will sell its oncology business to Servier for $2 billion plus royalties equal to 5% of net sales of its TIBSOVO® drug in the United States. After the deal closes, the company intends to spend at least $1.2 billion to return capital to shareholders and focus on developing and promoting its drugs to treat genetic diseases. It is expected to close in Q2 2021, subject to Agios shareholder approval.
Agios will sell its oncology business to Servier for $2 billion plus royalties equal to 5% of net sales of its TIBSOVO® drug in the United States. After the deal closes, the company intends to spend at least $1.2 billion to return capital to shareholders and focus on developing and promoting its drugs to treat genetic diseases. It is expected to close in Q2 2021, subject to Agios shareholder approval. 
investor.agios.com
English (US) 